Wed, September 16, 2009
Tue, September 15, 2009
Mon, September 14, 2009
Fri, September 11, 2009
Thu, September 10, 2009
Wed, September 9, 2009
Tue, September 8, 2009
Sun, September 6, 2009
Fri, September 4, 2009
Thu, September 3, 2009
Wed, September 2, 2009
Tue, September 1, 2009
Mon, August 31, 2009
Fri, August 28, 2009
Thu, August 27, 2009
Wed, August 26, 2009
Tue, August 25, 2009
Mon, August 24, 2009
Sun, August 23, 2009
Fri, August 21, 2009
Thu, August 20, 2009
Wed, August 19, 2009
Tue, August 18, 2009
Mon, August 17, 2009
Sun, August 16, 2009
Fri, August 14, 2009
Thu, August 13, 2009
Wed, August 12, 2009
Tue, August 11, 2009
Mon, August 10, 2009
Fri, August 7, 2009
Thu, August 6, 2009
Wed, August 5, 2009
Tue, August 4, 2009
Mon, August 3, 2009
Sat, August 1, 2009
Fri, July 31, 2009
Thu, July 30, 2009
Wed, July 29, 2009
Tue, July 28, 2009
Mon, July 27, 2009
Sat, July 25, 2009
Fri, July 24, 2009
Thu, July 23, 2009

ConjuChem announces securityholder approval for the $5 million non-dilutive financing


//health-fitness.news-articles.net/content/2009/ .. al-for-the-5-million-non-dilutive-financing.html
Published in Health and Fitness on Saturday, August 22nd 2009 at 13:47 GMT by Market Wire   Print publication without navigation


 MONTREAL, Aug. 19 /CNW/ - ConjuChem Biotechnologies Inc. ("ConjuChem") (TSX:CJB) announced today that the securityholders of ConjuChem (the "Securityholders") approved the previously announced plan of arrangement (the "Arrangement") at the special meeting of the Securityholders held today in Montréal. Pursuant to the Arrangement, ConjuChem will receive $5 million in new, non-dilutive capital. About ConjuChem Biotechnologies Inc. ConjuChem, a developer of next generation medicines from therapeutic peptides, creates long-acting compounds based on its proprietary bioconjugation platform technology. ConjuChem has two major development programs: PC-DAC(TM):Exendin-4, a GLP-1 receptor agonist in Phase II clinical development and PC-Insulin, a long-acting basal insulin in preclinical development. Detailed descriptions of ConjuChem and its technologies can be viewed on ConjuChem's website [ www.conjuchem.com ]. Forward-Looking Statements This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect ConjuChem's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the obtaining of court and other regulatory approvals and consents, the satisfaction of closing conditions, adjustment provisions relating to the proceeds of the transaction, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in ConjuChem's ongoing filings with the Canadian securities regulatory authorities which filings can be found at [ www.sedar.com ]. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. ConjuChem undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws. 
For further information: Mark Perrin, President and CEO, ConjuChem Biotechnologies Inc., (514) 844-5558 ext. 311, [ perrin@conjuchem.com ]; James Smith, Investor Relations, (416) 815-0700 ext. 229, [ JSmith@equicomgroup.com ]

Publication Contributing Sources